AUTHOR=Palmer Joshua D. , Chavez Gordon , Furnback Wesley , Chuang Po-Ya , Wang Bruce , Proescholdt Christina , Tang Chao-Hsiun 

TITLE=Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.772261

DOI=10.3389/fonc.2021.772261

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>To date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.</p></sec><sec><title>Methods</title><p>A survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the USA (<italic>n</italic> = 2,182) and Europe (<italic>n</italic> = 633). The survey included patient-reported demographic and clinical information, as well as EuroQol’s EQ-5D-5L and visual analogue scale (EQ-VAS) overall health score.</p></sec><sec><title>Results</title><p>A total of 1,106 applicable patients responded to the survey (USA = 782 and Europe = 324), with a mean age of 58.6 years (SD = 12.3). The average time since diagnosis and time using TTFields were 21.5 months (SD = 25.1) and 13.5 months (SD = 13.2), respectively. Over 61% of patients had been diagnosed at least 1 year prior and 28.4% at least 2 years prior; 45 patients (4.2%) had been diagnosed at least 5 years prior. Progressed disease was reported in 307 patients, while 690 reported non-progressed disease. Regression analyses showed that GBM disease progression and older age had predictable negative associations (<italic>p</italic> &lt; 0.001) with most EQ-5D-5L dimensions and the EQ-VAS. However, longer time since diagnosis was associated with improved self-care (<italic>p</italic> &lt; 0.05), usual activities (<italic>p</italic> &lt; 0.01), and EQ-VAS (<italic>p</italic> &lt; 0.05) overall and in patients with progressed disease (<italic>p</italic> &lt; 0.01, <italic>p</italic> &lt; 0.05, and <italic>p</italic> &lt; 0.01, respectively). Additionally, longer time using TTFields was associated with improved mobility (<italic>p</italic> &lt; 0.05), self-care (<italic>p</italic> &lt; 0.001), usual activities (<italic>p</italic> &lt; 0.01), and EQ-VAS (<italic>p</italic> &lt; 0.01) overall; with improved EQ-VAS in progression-free patients (<italic>p</italic> &lt; 0.05); and with improved mobility (<italic>p</italic> &lt; 0.05), self-care (<italic>p</italic> &lt; 0.01), usual activities (<italic>p</italic> &lt; 0.05), and EQ-VAS (<italic>p</italic> &lt; 0.05) in patients with progressed disease.</p></sec><sec><title>Conclusion</title><p>This is the largest real-world study of patient-reported quality of life in GBM and TTFields treatment to date. It shows unsurprising negative associations between quality of life and disease progression and older age, as well as more novel, positive associations between quality of life and longer time since diagnosis and time using TTFields therapy.</p></sec>